Journal of Korean Biological Nursing Science

Korean society of Biological Nursing Science (한국기초간호학회)
권호 표지
DOI QR코드

DOI QR Code

Factors Related to N-Terminal Pro-B-Type Natriuretic Peptide as a Biomarker for Heart Failure

  • Received : 2016.10.20
  • Accepted : 2016.11.24
  • Published : 2016.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: This study aimed to examine the relationships between the N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels with the sociodemographic and clinical factors, self-care behaviors, and the physical symptom experiences in patients with heart failure. Methods: This cross-sectional study utilized a convenience sample of adult outpatients and inpatients who attended a cardiology department in a tertiary hospital in Seoul, Korea. The data from 154 patients with heart failure were collected using a questionnaire, and their clinical data were extracted from their electronic medical records. Results: Compared with the patients with high NT-proBNP levels, those with low NT-proBNP levels had significantly lower physical symptom experiences scores. Patients with low- and mid-NT-proBNP levels were more likely to be employed compared with those with high NT-proBNP levels. Patients with low NT-proBNP levels had higher left ventricular ejection fractions, and were less likely to have arrhythmias and comorbidities. Conclusion: The results from this study showed that patients with more severe heart failure had higher physical symptom experiences scores; hence, individualizing treatment approaches based on heart failure severity is necessary.

Keywords

References

  1. Fang JC, Ewald GA, Allen LA, Butler J, Westlake Canary CA, Colvin-Adams M, et al. Advanced (stage D) heart failure: a statement from the Heart Failure Society of America Guidelines Committee. Journal of Cardiac Failure. 2015; 21(6):519-534. http://dx.doi.org/10.1016/j.cardfail.2015.04.013
  2. Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. Journal of the American College of Cardiology. 2013;62(4):263-271. http://dx.doi.org/10.1016/j.jacc.2013.02.092
  3. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6-e245. http://dx.doi.org/10.1161/CIR.0b013e31828124ad
  4. Han SW, Ryu KH, Chae SC, Yang DH, Shin MS, Lee SH, et al. Multicenter analysis of clinical characteristics and prognostic factors of patients with congestive heart failure in Korea. Korean Circulation Journal. 2015;35(5):357-361. http://dx.doi.org/10.4070/kcj.2005.35.5.357
  5. Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. Journal of the American College of Cardiology. 2014;63(12):1123-1133. http://dx.doi.org/10.1016/j.jacc.2013.11.053
  6. Allen F, Haroun R. Systematic review of the societal cost and economic burden associated with chronic heart failure. Value in Health. 2015;18(3):A139. http://dx.doi.org/10.1016/j.jval.2015.03.810
  7. Gheorghiade M, Vaduganathan M. Rehospitalization for heart failure: problems and perspectives. Journal of the American College of Cardiology. 2013;61(4):391-403. http://dx.doi.org/10.1016/j.jacc.2012.09.038
  8. Sethares KA, Chin E. Predictors of delay in heart failure patients and consequences for outcomes. Current Heart Failure Reports. 2015;12(1):94-105. http://dx.doi.org/10.1007/s11897-014-0241-5
  9. Steinhubl S, Sun J, Vijayakrishnan R, Byrd R, Daar Z, Gotz D, et al. A3-2: The signs and symptoms of heart failure are frequently documented to wax and wane in the years prior to a clinical diagnosis of heart failure: data from 4,644 patients followed in primary care. Clinical Medicine & Research. 2013;11(3):134-135. http://dx.doi.org/10.3121/cmr.2013.1176.a3-2
  10. Herr JK, Salyer J, Flattery M, Goodloe L, Lyon DE, Kabban CS, et al. Heart failure symptom clusters and functional status-a crosssectional study. Journal of Advanced Nursing. 2015;71(6):1274-1287. http://dx.doi.org/10.1111/jan.12596
  11. Gluba A, Bielecka-Dabrowa A, Mikhailidis DP, Wong ND, Franklin SS, Rysz J, et al. An update on biomarkers of heart failure in hypertensive patients. Journal of Hypertension. 2012;30(9):1681-1689. http://dx.doi.org/10.1097/hjh.0b013e32835f668c
  12. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology. 2013;62(16):e147-e239. http://dx.doi.org/10.1016/j.jacc.2013.05.019
  13. Stienen S, Salah K, Dickhoff C, Carubelli V, Metra M, Magrini L, et al. N-terminal pro-B-type natriuretic peptide (NT-proBNP) measurements until a 30% reduction is attained during acute decompensated heart failure admissions and comparison with discharge NT-proBNP levels: implications for in-hospital guidance of treatment. Journal of Cardiac Failure. 2015;21(11):930-934. http://dx.doi.org/10.1016/j.cardfail.2015.07.011
  14. Galasko GI, Lahiri A. What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease? European Heart Journal. 2005;26(21):2269-2276. http://dx.doi.org/10.1093/eurheartj/ehi410
  15. Bernstein LH, Zions MY, Haq SA, Zarich S, Rucinski J, Seamonds B, et al. Effect of renal function loss on NT-proBNP level variations. Clinical Biochemistry. 2009;42(10):1091-1098. http://doi.org/10.1016/j.clinbiochem.2009.02.027
  16. Lee CS, Moser DK. Biomarkers of myocardial stress and systemic inflammation in patients who engage in heart failure self-care management. Journal of Cardiovascular Nursing. 2011;26(4):321-328. http://dx.doi.org/10.1097/jcn.0b013e31820344be
  17. Peng CYJ, Lee KL. An introduction to logistic regression analysis and reporting. The Journal of Educational Research. 2002;96(1):3-14. http://dx.doi.org/ 10.4135/9781412983433.n4
  18. Riegel B, Carlson B. Development and testing of a clinical tool measuring self-management of heart failure. Heart & Lung: The Journal of Acute and Critical Care. 2000;29(1):4-15. http://dx.doi.org/10.1016/s0147-9563(00)90033-5
  19. Song EK, Kim CJ. Factors influencing functional status in patients with heart failure. Journal of Korean Academy of Nursing. 2006;36(5):853-862. https://doi.org/10.4040/jkan.2006.36.5.853
  20. Son YJ, Kim SH. The influences of cognitive function on adherence to self care in elderly patients with heart failure. Korean Journal of Health Promotion. 2010;10(2):61-70.
  21. Jaarsma T, Arestedt KF. The European Heart Failure Self-care Behaviour scale revised into a nine-item scale (EHFScB-9): a reliable and valid international instrument. European Journal of Heart Failure. 2009;11(1):99-105. http://dx.doi.org/10.1093/eurjhf/hfn007
  22. Gaggin HK, Truong QA, Rehman SU, Mohammed AA, Bhardwaj A, Parks KA, et al. Characterization and prediction of natriuretic peptide "nonresponse" during heart failure management: results from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) and the NTproBNP-Assisted Treatment to Lessen Serial Cardiac Readmissions and Death (BATTLESCARRED) study. Congestive Heart Failure. 2013;19(3):135-142. http://dx.doi.org/10.1111/chf.12016
  23. Kato N, Kinugawa K, Ito N, Yao A, Watanabe M, Imai Y, et al. Adherence to self-care behavior and factors related to this behavior among patients with heart failure in Japan. Heart & Lung: The Journal of Acute and Critical Care. 2009;38(5):398-409. http://dx.doi.org/10.1016/j.hrtlng.2008.11.002
  24. Zhang Y, Chen A. Association between baseline natriuretic peptides and atrial fibrillation recurrence after catheter ablation. International Heart Journal. 2016;57(2):183-189. http://dx.doi.org/10.1536/ihj.15-355
  25. Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. The Lancet. 2015;386(9989):154-162. http://dx.doi.org/10.1016/s0140-6736(14)61774-8
  26. Gonell RLR, Arias-Mendoza A, Zarate JS, Pacheco HG, Sanchez CRM, Sangabriel AA, et al. Prognosis of acute decompensated heart failure in patients with preserved and reduced left ventricular ejection fraction based on N-terminal pro-B-type natriuretic peptide at admission. Journal of the American College of Cardiology. 2014;63(12):A794. http://dx.doi.org/10.1016/s0735-1097(14)60794-4
  27. Ikonomidis I, Nikolaou M, Dimopoulou I, Paraskevaidis I, Lekakis J, Mavrou I, et al. Association of left ventricular diastolic dysfunction with elevated NT-pro-BNP in general intensive care unit patients with preserved ejection fraction: a complementary role of tissue Doppler imaging parameters and NT-pro-BNP levels for adverse outcome. Shock. 2010;33(2):141-148. http://dx.doi.org/10.1097/shk.0b013e3181ad31f8
  28. Mansoor A, Althoff K, Gange S, Anastos K, Dehovitz J, Minkoff H, et al. Elevated NT-pro-BNP levels are associated with comorbidities among HIV-infected women. AIDS Research and Human Retroviruses. 2009;25(10):997-1004. http://dx.doi.org/10.1089/aid.2009.0038
  29. Maries L, Manitiu I. Diagnostic and prognostic values of B-type natriuretic peptides (BNP) and N-terminal fragment brain natriuretic peptides (NT-pro-BNP). Cardiovascular Journal of Africa. 2013;24(7):286-289. http://dx.doi.org/10.5830/cvja-2013-055
  30. Sandersvan Wijk S, Muzzarelli S, Neuhaus M, Kiencke S, Maeder M, Estlinbaum W, et al. Safety and tolerability of intensified, Nterminal pro brain natriuretic peptideguided compared with standard medical therapy in elderly patients with congestive heart failure: results from TIMELCHF. European Journal of Heart Failure. 2013;15(8):910-918. http://dx.doi.org/10.1093/eurjhf/hft079